REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • October 14th, 2021 • Quotient LTD • In vitro & in vivo diagnostic substances
This Agreement is being entered into in connection with the execution and delivery of the Fourth Supplemental Indenture, dated as of October 13, 2021, by and among the Company, the guarantors party thereto, and the Holders (the “Fourth Supplemental Indenture”) which supplements and amends the Indenture, dated as of October 14, 2016 by and among Company, the guarantors party thereto, and the Holders (as subsequently amended, the “Indenture”). The Holders collectively own all of the Company’s 12.00% Senior Secured Notes issued pursuant to the terms of the Indenture (the “Notes”). In consideration of the Holders’ execution and delivery of the consents that are required for the effectiveness of the Fourth Supplemental Indenture, the Company has issued to the Holders (1) an aggregate of 932,772 of the Company’s ordinary shares, nil par value per share (the “Consent Shares”) and (2) warrants (the “Warrants”) to purchase an aggregate of 1,844,020 of the Company’s ordinary shares, nil par valu
FOURTH SUPPLEMENTAL INDENTUREFourth Supplemental Indenture • October 14th, 2021 • Quotient LTD • In vitro & in vivo diagnostic substances • New York
This Fourth Supplemental Indenture (this “Supplemental Indenture”), is entered into as of October 13, 2021, among Quotient Limited, a public limited liability no par value company formed under the laws of Jersey, Channel Islands (the “Issuer”), the Guarantors party hereto, and U.S. Bank National Association, as trustee (the “Trustee”) and as collateral agent (the “Collateral Agent”).
